A blood test to study lung cancer and move towards more personalized treatments
Scientific Culture and Innovation Unit
A group of researchers from the Puerta de Hierro-Segovia Institute of Research (IDIPHISA) and the Puerta de Hierro University Hospital in Majadahonda has validated a new tool that analyzes the genetic alterations of lung cancer based on a blood sample. This test provides information that could, among other things, help in choosing a personalized treatment, taking into account the individual characteristics of each patient.

Lung cancer is the leading cause of cancer-related death worldwide. According to data from 2024, it is estimated that 2.6 million new cases and 1.8 million deaths were diagnosed worldwide. The main problem with this type of cancer is that two-thirds of patients are diagnosed at an advanced stage, where therapeutic options and patient prognosis are limited.
In recent years, new targeted therapies have been developed to treat these patients. However, in order to select the most appropriate treatment for each case, it is essential to quickly and reliably know the genetic characteristics of each tumor. This not only allows for personalized treatment, but in some cases also improves the survival results of patients. However, obtaining a sample of the tumor to analyze it is not always possible, which is why other non-invasive alternatives are emerging. This is the case of liquid biopsy, which allows detecting the DNA released by the tumor into the bloodstream through a blood test.
In this context, a team of researchers from the Liquid Biopsy Group of the Puerta de Hierro-Segovia Institute of Health Research (IDIPHISA) and the Medical Oncology Service of the Puerta de Hierro University Hospital in Majadahonda has validated a new tool that allows the analysis with high precision of more than 80 genes related to various types of cancer, including lung cancer, from a blood sample. This is a new next-generation sequencing panel (NGS) known by the name Illumina Solid Tumor Panel 80 (IST80 Plus)
The work, published in the journal The Journal of Loquid Biopsy And led by Dr. Pilar Mediavilla Medel and Dr. Atocha Romero, it represents a major step forward towards precision medicine based on the characteristics of each patient.
Liquid biopsy: an alternative to study lung cancer
Liquid biopsy is a method that allows detecting tumor material or the DNA released by the tumor into the bloodstream, identifying its mutations, monitoring the tumor, studying the response to treatment, or even the mechanisms that the tumor itself develops when it does not respond to drugs. Conventional biopsies require extracting a sample of tumor tissue, which is often complicated, as in the case of lung cancer, where it is approached through a puncture or surgical intervention. However, this technique is performed by simply extracting blood.
As the tumor grows, some of its cells die and release small fragments of their genetic material, that is, their DNA, which pass into the bloodstream. This is what is known as circulating tumor DNA or ctDNA, for its acronym in English (circulating tumor DNAThese fragments constitute a kind of molecular trail that the tumor leaves behind and that we can analyze through a blood test. This is a way of studying the characteristics or mutations of the tumor without the need to obtain a sample of the tumor tissue.
Greater precision in the analysis of tumor DNA
The goal of this work was to validate a new tool that would allow the detection of mutations in genes related to lung cancer, based on samples of this tumor material or ctDNA. This is a new next-generation sequencing panel (NGS), a technology that allows analyzing sequences of DNA of interest. In other words, it enables reading the DNA of a patient’s tumor in regions of interest quickly and accurately, which helps better understand the characteristics of the cancer and contribute to selecting the most appropriate treatment for each patient.
To do this, the researchers used samples from patients, standardized commercial samples as controls, and cell models with known mutations, using a panel that allows the analysis of 87 genes related to cancer, known as the Illumina Solid Tumor Panel 80 (IST80 Plus).
The results showed that of the 135 alterations that the panel could detect, 129 were identified in the samples, achieving a sensitivity of 95.56%. In addition, they observed that this technique presented a very high ability to avoid obtaining false positive results, that is, detecting mutations that are not actually present, with a specificity close to 100%. However, the authors point out that negative results should be interpreted with caution.
Advances in personalized oncology
In this work, the development of a new tool, IST80 Plus, represents a step forward in personalized medicine for lung cancer. Techniques such as the one presented in this work allow analyzing genetic alterations in the tumor from a simple blood sample, avoiding in many cases more invasive procedures and facilitating the acquisition of molecular information about the disease.
Although the results of this study are promising, further research is still needed to confirm its usefulness in a larger number of patients.
This type of technology can help healthcare professionals choose the most appropriate treatment, so it not only seeks to develop more effective treatments, but also to ensure that each person receives more personalized care tailored to the characteristics of their disease.
References:
Mediavilla-Medel P, Serna-Blasco R, de Lope LR, Festa AR, Alcalde CG, De la Torre-Capitan E, García-Simon N, Martin-Doblado AS, Provencio M, Romero A, Validation of a ctDNA-Based Comprehensive Genomic Profiling Panel (IST80 Plus) for Advanced Non-Small Cell LungCancer, The Journal of Liquid Biopsy, https://doi.org/10.1016/j.jlb.2026.100674
International Agency for Research on Cancer. (s. f.). Lung cancer. Global Cancer Observatory. https://gco.iarc.who.int/today/en/fact-sheets-cancers/15/lung
Spanish Association Against Cancer. (2026). Prognosis of lung cancer. https://www.contraelcancer.es/es/todo-sobre-cancer/tipos-cancer/cancer-pulmon/evolucion-cancer-pulmon

